Follow RSS for latest reports on this topicEnbrel - Market Research and Reports

Technical Background

Tumor necrosis factor (TNF) is a substance made by your body's immune system. People with inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis have too much TNF in their bodies. ENBREL reduces levels of the active form of TNF.  Further details can be viewed:

  • Tumor Necrosis Factor TNF
  • Cytokine Tumour Necrosis Factor (TNF)

Mechanism of Action:

ENBREL (etanercept) is grouped within a class of medications called biologic response modifiers, or biologics. By working on the immune system, biologics block proteins that contribute to the disease process. Because ENBREL suppresses the immune system, patients are at a greater risk for getting serious infections.

Enbrel (etanercept) is a soluble TNF-receptor fusion protein used for the treatment of moderate to severe active RA patients who are unresponsive to one or more DMARDs. Enbrel is a leading biologic agent and is approved for multiple immunological indications including psoriasis and ankylosing spondylitis. Enbrel is a bivalent p75 receptor linked to the Fc portion of human IgG. Enbrel binds to lymphotoxin and TNF-alpha, blocking its interaction with cell surface TNF receptors, thus preventing synovial inflammation.

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...

or can supply a pro-forma invoice if required.

We Stock...